Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 10 | 2007 | 313 | 1.270 |
Why?
|
| Orthopedics | 4 | 2008 | 134 | 0.660 |
Why?
|
| Sarcoma | 3 | 2009 | 222 | 0.460 |
Why?
|
| Osteosarcoma | 7 | 2005 | 158 | 0.460 |
Why?
|
| Orthopedic Procedures | 2 | 2004 | 150 | 0.370 |
Why?
|
| Education, Medical, Graduate | 2 | 2004 | 425 | 0.310 |
Why?
|
| Neoplasm Staging | 4 | 2007 | 2017 | 0.260 |
Why?
|
| Argon | 1 | 2007 | 10 | 0.260 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2007 | 15 | 0.250 |
Why?
|
| Laser Coagulation | 1 | 2007 | 55 | 0.240 |
Why?
|
| Advisory Committees | 1 | 2006 | 90 | 0.230 |
Why?
|
| Accreditation | 1 | 2006 | 73 | 0.230 |
Why?
|
| Limb Salvage | 1 | 2005 | 38 | 0.230 |
Why?
|
| Career Mobility | 1 | 2005 | 37 | 0.220 |
Why?
|
| Femur | 1 | 2005 | 107 | 0.220 |
Why?
|
| Hallux Valgus | 1 | 2004 | 6 | 0.210 |
Why?
|
| Faculty, Medical | 1 | 2005 | 187 | 0.200 |
Why?
|
| Fellowships and Scholarships | 2 | 2008 | 145 | 0.190 |
Why?
|
| Epithelioid Cells | 1 | 2003 | 13 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 394 | 0.190 |
Why?
|
| Hemangioma | 1 | 2003 | 63 | 0.190 |
Why?
|
| Lymphoma | 1 | 2003 | 247 | 0.180 |
Why?
|
| Leadership | 1 | 2003 | 148 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 257 | 0.170 |
Why?
|
| Internship and Residency | 3 | 2008 | 1090 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2006 | 822 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2003 | 621 | 0.150 |
Why?
|
| Prognosis | 4 | 2006 | 3911 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2007 | 1448 | 0.110 |
Why?
|
| Humans | 17 | 2009 | 93515 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2005 | 1524 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2009 | 10164 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2003 | 889 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 1061 | 0.080 |
Why?
|
| Adult | 7 | 2009 | 27918 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2009 | 314 | 0.060 |
Why?
|
| Survival Rate | 3 | 2009 | 1948 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 2544 | 0.060 |
Why?
|
| Female | 8 | 2009 | 48702 | 0.060 |
Why?
|
| S100 Proteins | 1 | 2005 | 51 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2006 | 504 | 0.050 |
Why?
|
| Adolescent | 3 | 2007 | 9606 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 876 | 0.050 |
Why?
|
| Male | 7 | 2009 | 44557 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2005 | 314 | 0.050 |
Why?
|
| Hemangioendothelioma | 1 | 2003 | 9 | 0.050 |
Why?
|
| Ameloblastoma | 1 | 2003 | 9 | 0.050 |
Why?
|
| Neurofibrosarcoma | 1 | 2003 | 5 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2004 | 93 | 0.050 |
Why?
|
| Bone Marrow Examination | 1 | 2003 | 40 | 0.050 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2003 | 23 | 0.050 |
Why?
|
| Organizational Objectives | 1 | 2003 | 22 | 0.050 |
Why?
|
| Sarcoma, Ewing | 1 | 2003 | 42 | 0.050 |
Why?
|
| Chondrosarcoma | 1 | 2003 | 54 | 0.050 |
Why?
|
| Chordoma | 1 | 2003 | 42 | 0.050 |
Why?
|
| United States | 3 | 2008 | 7622 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 128 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2006 | 2365 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 206 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 43 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 409 | 0.050 |
Why?
|
| Fibula | 1 | 2003 | 31 | 0.050 |
Why?
|
| Tibia | 1 | 2003 | 80 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 189 | 0.050 |
Why?
|
| Chromans | 1 | 2002 | 28 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2004 | 3476 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2002 | 278 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 77 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 223 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2003 | 884 | 0.040 |
Why?
|
| Thiazoles | 1 | 2002 | 124 | 0.040 |
Why?
|
| Tretinoin | 1 | 2002 | 129 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1917 | 0.040 |
Why?
|
| Radiography | 1 | 2003 | 790 | 0.040 |
Why?
|
| Chicago | 1 | 2005 | 1464 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2004 | 457 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 776 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2002 | 603 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2002 | 439 | 0.040 |
Why?
|
| Biopsy | 1 | 2003 | 1175 | 0.040 |
Why?
|
| Curriculum | 1 | 2004 | 594 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 1713 | 0.040 |
Why?
|
| Middle Aged | 3 | 2009 | 27573 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2495 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2004 | 3829 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1721 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2005 | 416 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 2585 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2003 | 9099 | 0.020 |
Why?
|
| Child | 1 | 2004 | 7355 | 0.020 |
Why?
|
| Risk Factors | 1 | 2003 | 5899 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2005 | 1028 | 0.020 |
Why?
|
| Cell Movement | 2 | 2005 | 809 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 2303 | 0.020 |
Why?
|
| Mutation | 1 | 2002 | 4272 | 0.020 |
Why?
|
| Mice | 1 | 2005 | 12269 | 0.020 |
Why?
|
| Aged | 2 | 2009 | 20434 | 0.020 |
Why?
|
| Epirubicin | 1 | 2009 | 14 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 37 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 204 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 284 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 472 | 0.020 |
Why?
|
| Extremities | 1 | 2009 | 176 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2009 | 321 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 829 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 512 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 568 | 0.020 |
Why?
|
| Career Choice | 1 | 2008 | 156 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A6 | 1 | 2005 | 12 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2008 | 494 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 399 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2005 | 824 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 293 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 2002 | 38 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2002 | 49 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2002 | 47 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 86 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 266 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 123 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 315 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1799 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 543 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 450 | 0.010 |
Why?
|
| beta Catenin | 1 | 2002 | 265 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 693 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1518 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 2544 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1741 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 2755 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1914 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 6930 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 1338 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1621 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 1691 | 0.010 |
Why?
|
| Time Factors | 1 | 2002 | 5410 | 0.010 |
Why?
|
| Animals | 1 | 2005 | 28155 | 0.000 |
Why?
|